Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in acute traumatic cervical spinal cord injury
2019-003752-36Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in spinal cord injury (SCI) and acute cervical spinal cord injury (ACSCI) comparing Elezanumab with Placebo (2 arms). Primary endpoint: Upper Extremity Motor Score (UEMS). Started May 2020; status: active.
02
Drugs
elezanumab
03
Conditions
spinal cord injury (SCI)acute cervical spinal cord injury (ACSCI)
Beyond the preview
Go deeper on 2019-003752-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003752-36.